Speaking the Language of the Business, with Jamey Lindholm

Quality culture isn't built by SOPs. It's built in the small moments when a leader reinforces the right behaviour or lets the wrong one slide.

Speaking the Language of the Business, with Jamey Lindholm.

In today's episode I was joined by Jamey Lindholm, Vice President of Quality at R1 Therapeutics. I really wanted to speak to Jamey because she has led Quality through nearly every stage a career in this industry can throw at you: a first-in-class FDA approval at Seres Therapeutics, an acquisition by Merck KGaA at Springworks, and now building a Quality function completely from zero as R1's very first Quality hire. She has strong, hard-won views on how to get each of those right.

Jamey's journey started almost by accident. She fell into a QC chemistry job at a small biotech straight out of university, got laid off a year later when the company ran out of funding, and then spent the next 20 years at Biogen, where she built the foundation of what she now calls "what good looks like" in Quality. From there she moved to Seres Therapeutics, where she led end to end Quality through the first FDA approval of a microbiome-derived oral therapy, then to Springworks through its acquisition by Merck KGaA, and now to R1 Therapeutics as its first Quality hire.

What comes through across the whole conversation is a leader who has thought deeply about the difference between compliance and culture. Jamey is clear that Quality earns its seat at the leadership table not by enforcing SOPs, but by translating compliance into risk, into regulatory consequence, into business decisions that leadership teams actually understand. She is equally clear that the industry has a visibility problem. Almost nobody chooses Quality as a career at school, and she believes that is something the industry has an obligation to fix.

We talk about the following:

Why 20 years at a large pharma company can make the move into a startup harder, not easierThe difference between managing Quality operations and being responsible for end-to-end Quality at a small companyWhy "quality risks are business risks" changes how a leadership team makes decisionsWhat actually builds quality culture, and why it isn't SOPsThe moment Seres received FDA approval for Vowst, and why it felt different from anything Jamey experienced at BiogenWhy it's never too early to bring in a permanent Head of Quality, and what that decision signals about a company's cultureWhy Quality is invisible as a career choice to STEM students, and what the industry can do about it

Jamey is a thoughtful, pragmatic quality leader who understands how to balance compliance, collaboration and business reality in complex development environments. If you are a quality professional working in an early-stage biotech and trying to build the right systems with limited resources, then this episode is for you. Thank you Jamey for sharing your incredible journey. Hope everyone enjoys the show.

WHO THIS EPISODE IS FOR

A Head of Quality or VP Quality building a function from scratch at a startupA big pharma quality professional considering a move into biotechA founder or CEO deciding when to bring in a permanent Head of QualityA quality manager trying to build genuine culture, not just documentationA STEM student or early-career scientist who has never considered Quality as a career path

Timestamps:

(00:00) Introduction to Jamey Lindholm and Her Career Journey